You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTroleandomycin
Accession NumberDB01361
TypeSmall Molecule
GroupsApproved
DescriptionA macrolide antibiotic that is similar to erythromycin.
Structure
Thumb
Synonyms
TAO
Triacetyloleandomycin
Troleandomycin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
TaoNot Available
TriocetinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIC4DZ64560D
CAS number2751-09-9
WeightAverage: 813.9684
Monoisotopic: 813.451070479
Chemical FormulaC41H67NO15
InChI KeyInChIKey=LQCLVBQBTUVCEQ-QTFUVMRISA-N
InChI
InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1
IUPAC Name
(3R,5R,6S,7S,8R,11R,12S,13R,14S,15S)-14-{[(2S,3R,4S,6R)-3-(acetyloxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-12-{[(2R,4S,5S,6S)-5-(acetyloxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxaspiro[2.13]hexadecan-6-yl acetate
SMILES
CO[[email protected]]1C[[email protected]](O[[email protected]]2[[email protected]](C)[C@@H](O[C@@H]3O[[email protected]](C)C[C@@H]([[email protected]]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[[email protected]](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolides and analogues
Sub ClassNot Available
Direct ParentMacrolides and analogues
Alternative Parents
Substituents
  • Macrolide
  • Amino sugar
  • Desosamine
  • Amino saccharide
  • Oxane
  • Monosaccharide
  • Acetate salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactone
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Oxirane
  • Dialkyl ether
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of Pneumococcal pneumonia due to susceptible strains and group A beta-hemolytic streptococcal infections of the upper respiratory tract.
PharmacodynamicsTroleandomycin is a macrolide antibiotic that is similar to erythromycin. It is active in vitro against the following gram-positive organisms: Streptococcus pyogenes and Diplococcus pneumoniae.
Mechanism of actionTroleandomycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the "P" or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the "A" or acceptor site to the "P" or donor site is prevented, and subsequent protein synthesis is inhibited.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategorySMPDB ID
Troleandomycin Action PathwayDrug actionSMP00730
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9048
Blood Brain Barrier-0.945
Caco-2 permeable-0.522
P-glycoprotein substrateSubstrate0.662
P-glycoprotein inhibitor IInhibitor0.9188
P-glycoprotein inhibitor IINon-inhibitor0.631
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9075
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9223
Ames testAMES toxic0.5213
CarcinogenicityNon-carcinogens0.8564
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity2.2177 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9881
hERG inhibition (predictor II)Non-inhibitor0.9163
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0192 mg/mLALOGPS
logP3.76ALOGPS
logP4.3ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)16.75ChemAxon
pKa (Strongest Basic)7.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area184.19 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity201.15 m3·mol-1ChemAxon
Polarizability86.08 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesJ01FA08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Troleandomycin.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Troleandomycin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Troleandomycin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Troleandomycin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Troleandomycin.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Troleandomycin.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Troleandomycin.
AmiodaroneThe metabolism of Troleandomycin can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Troleandomycin.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Troleandomycin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Troleandomycin.
AprepitantThe serum concentration of Troleandomycin can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Troleandomycin.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Troleandomycin resulting in a loss in efficacy.
AtazanavirThe metabolism of Troleandomycin can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Troleandomycin.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Troleandomycin.
AtomoxetineThe metabolism of Troleandomycin can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Troleandomycin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Troleandomycin.
BexaroteneThe serum concentration of Troleandomycin can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Troleandomycin can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Troleandomycin.
BortezomibThe metabolism of Troleandomycin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Troleandomycin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Troleandomycin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Troleandomycin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Troleandomycin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Troleandomycin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Troleandomycin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Troleandomycin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Troleandomycin.
CarbamazepineThe metabolism of Troleandomycin can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Troleandomycin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Troleandomycin.
CeritinibThe serum concentration of Troleandomycin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Troleandomycin.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Troleandomycin.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Troleandomycin.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Troleandomycin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Troleandomycin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Troleandomycin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Troleandomycin.
ClarithromycinThe metabolism of Troleandomycin can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Troleandomycin.
ClemastineThe metabolism of Troleandomycin can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Troleandomycin.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Troleandomycin.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Troleandomycin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Troleandomycin.
ClotrimazoleThe metabolism of Troleandomycin can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Troleandomycin.
CobicistatThe metabolism of Troleandomycin can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Troleandomycin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Troleandomycin.
ConivaptanThe serum concentration of Troleandomycin can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Troleandomycin.
CrizotinibThe metabolism of Troleandomycin can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Troleandomycin.
CyclosporineThe metabolism of Troleandomycin can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Troleandomycin.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Troleandomycin.
DabrafenibThe serum concentration of Troleandomycin can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Troleandomycin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Troleandomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Troleandomycin.
DarunavirThe metabolism of Troleandomycin can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Troleandomycin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Troleandomycin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Troleandomycin.
DeferasiroxThe serum concentration of Troleandomycin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Troleandomycin can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Troleandomycin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Troleandomycin.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Troleandomycin.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Troleandomycin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Troleandomycin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Troleandomycin.
DihydroergotamineThe metabolism of Troleandomycin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Troleandomycin.
DiltiazemThe metabolism of Troleandomycin can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Troleandomycin.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Troleandomycin.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Troleandomycin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Troleandomycin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Troleandomycin.
DoxycyclineThe metabolism of Troleandomycin can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Troleandomycin can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Troleandomycin.
EfavirenzThe serum concentration of Troleandomycin can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Troleandomycin.
EnzalutamideThe serum concentration of Troleandomycin can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Troleandomycin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Troleandomycin.
ErythromycinThe metabolism of Troleandomycin can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Troleandomycin.
Eslicarbazepine acetateThe serum concentration of Troleandomycin can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Troleandomycin.
EstriolThe serum concentration of Estriol can be increased when it is combined with Troleandomycin.
EstroneThe serum concentration of Estrone can be increased when it is combined with Troleandomycin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Troleandomycin.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Troleandomycin.
EtravirineThe serum concentration of Troleandomycin can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Troleandomycin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Troleandomycin.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Troleandomycin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Troleandomycin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Troleandomycin.
FluconazoleThe metabolism of Troleandomycin can be decreased when combined with Fluconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Troleandomycin.
FluvoxamineThe metabolism of Troleandomycin can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Troleandomycin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Troleandomycin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Troleandomycin can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Troleandomycin can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Troleandomycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Troleandomycin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Troleandomycin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Troleandomycin.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Troleandomycin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Troleandomycin.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Troleandomycin.
IdelalisibThe serum concentration of Troleandomycin can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Troleandomycin can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Troleandomycin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Troleandomycin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Troleandomycin.
IndinavirThe metabolism of Troleandomycin can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Troleandomycin.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Troleandomycin.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Troleandomycin.
IsavuconazoniumThe metabolism of Troleandomycin can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Troleandomycin can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Troleandomycin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Troleandomycin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Troleandomycin.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Troleandomycin.
KetoconazoleThe metabolism of Troleandomycin can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Troleandomycin.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Troleandomycin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Troleandomycin.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Troleandomycin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Troleandomycin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Troleandomycin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Troleandomycin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Troleandomycin.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Troleandomycin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Troleandomycin.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Troleandomycin.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Troleandomycin.
LopinavirThe metabolism of Troleandomycin can be decreased when combined with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Troleandomycin.
LovastatinThe metabolism of Troleandomycin can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Troleandomycin can be increased when it is combined with Luliconazole.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Troleandomycin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Troleandomycin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Troleandomycin.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Troleandomycin.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Troleandomycin.
MifepristoneThe metabolism of Troleandomycin can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Troleandomycin.
MitotaneThe serum concentration of Troleandomycin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Troleandomycin.
ModafinilThe serum concentration of Troleandomycin can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Troleandomycin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Troleandomycin.
NadololThe serum concentration of Nadolol can be increased when it is combined with Troleandomycin.
NafcillinThe serum concentration of Troleandomycin can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Troleandomycin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Troleandomycin.
NefazodoneThe metabolism of Troleandomycin can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Troleandomycin can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Troleandomycin.
NetupitantThe serum concentration of Troleandomycin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Troleandomycin can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Troleandomycin.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Troleandomycin.
NilotinibThe metabolism of Troleandomycin can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Troleandomycin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Troleandomycin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Troleandomycin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Troleandomycin.
OlaparibThe metabolism of Troleandomycin can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Troleandomycin.
OsimertinibThe serum concentration of Troleandomycin can be increased when it is combined with Osimertinib.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Troleandomycin.
PalbociclibThe serum concentration of Troleandomycin can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Troleandomycin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Troleandomycin.
PentobarbitalThe metabolism of Troleandomycin can be increased when combined with Pentobarbital.
PhenobarbitalThe metabolism of Troleandomycin can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Troleandomycin.
PhenytoinThe metabolism of Troleandomycin can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Troleandomycin.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Troleandomycin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Troleandomycin.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Troleandomycin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Troleandomycin.
PosaconazoleThe metabolism of Troleandomycin can be decreased when combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Troleandomycin.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Troleandomycin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Troleandomycin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Troleandomycin.
PrimidoneThe metabolism of Troleandomycin can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Troleandomycin.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Troleandomycin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Troleandomycin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Troleandomycin.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Troleandomycin.
QuinineThe serum concentration of Quinine can be increased when it is combined with Troleandomycin.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Troleandomycin.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Troleandomycin.
RanolazineThe metabolism of Troleandomycin can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Troleandomycin.
RifabutinThe metabolism of Troleandomycin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Troleandomycin can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Troleandomycin.
RifapentineThe metabolism of Troleandomycin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Troleandomycin.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Troleandomycin.
RitonavirThe metabolism of Troleandomycin can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Troleandomycin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Troleandomycin.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Troleandomycin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Troleandomycin.
SaquinavirThe metabolism of Troleandomycin can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Troleandomycin.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Troleandomycin.
SildenafilThe metabolism of Troleandomycin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Troleandomycin.
SiltuximabThe serum concentration of Troleandomycin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Troleandomycin can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Troleandomycin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Troleandomycin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Troleandomycin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Troleandomycin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Troleandomycin.
St. John's WortThe serum concentration of Troleandomycin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Troleandomycin can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Troleandomycin can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Troleandomycin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Troleandomycin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Troleandomycin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Troleandomycin.
TelaprevirThe metabolism of Troleandomycin can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Troleandomycin.
TelithromycinThe metabolism of Troleandomycin can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Troleandomycin.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Troleandomycin.
TiclopidineThe metabolism of Troleandomycin can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Troleandomycin.
TocilizumabThe serum concentration of Troleandomycin can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Troleandomycin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Troleandomycin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Troleandomycin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Troleandomycin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Troleandomycin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Troleandomycin.
VenlafaxineThe metabolism of Troleandomycin can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Troleandomycin.
VerapamilThe metabolism of Troleandomycin can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Troleandomycin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Troleandomycin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Troleandomycin.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Troleandomycin.
VoriconazoleThe metabolism of Troleandomycin can be decreased when combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Troleandomycin.
ZiprasidoneThe metabolism of Troleandomycin can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Deinococcus radiodurans (strain ATCC 13939 / DSM 20539 / JCM 16871 / LMG 4051 / NBRC 15346 / NCIMB 9279 / R1 / VKM B-1422)
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of ribosome
Specific Function:
Forms a cluster with L17 and L22, and with L22, a pair of "tweezers" that hold together all the domains of the 23S rRNA. Interacts with the antibiotic troleandomycin which blocks the peptide exit tunnel.
Gene Name:
rpmF
Uniprot ID:
P49228
Molecular Weight:
6791.905 Da
References
  1. Scharre KA, Eckels DD, Gershwin ME: Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5. [PubMed:6972981 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Translation repressor activity
Specific Function:
One of the primary rRNA binding proteins, this protein initially binds near the 5'-end of the 23S rRNA. It is important during the early stages of 50S assembly. It makes multiple contacts with different domains of the 23S rRNA in the assembled 50S subunit and ribosome.Protein L4 is a both a transcriptional repressor and a translational repressor protein; these two functions are independent of e...
Gene Name:
rplD
Uniprot ID:
P60723
Molecular Weight:
22086.36 Da
References
  1. Scharre KA, Eckels DD, Gershwin ME: Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5. [PubMed:6972981 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M: Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 1996 Jul;26(7):681-93. [PubMed:8819299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Klees TM, Sheffels P, Dale O, Kharasch ED: Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos. 2005 Mar;33(3):303-11. Epub 2004 Nov 22. [PubMed:15557344 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Ledirac N, de Sousa G, Fontaine F, Agouridas C, Gugenheim J, Lorenzon G, Rahmani R: Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab Dispos. 2000 Dec;28(12):1391-3. [PubMed:11095572 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  2. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:54 / Updated on August 17, 2016 12:23